Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing

Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.

BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).

Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale the manufacturing of retogatein (rhGAD65) ahead of commercialization.

The two companies are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.

The company has entered into an exclusive global licensing and research collaboration with a multinational consumer health company to expand the SiPore technology platform into consumer oral health through a partner-led approach.

The Board of Directors of the company has resolved to carry out a fully guaranteed rights issue of SEK 307 million.